

# Tosk Announces Clinical Study Results for TK-90 to Prevent Mucositis

*Tosk drug TK-90 successful in preventing painful, dose-limiting mucositis caused by common cancer therapies.*

MOUNTAIN VIEW, CALIFORNIA, USA, December 17, 2018 /EINPresswire.com/ -- Privately held biotechnology company, Tosk, Inc., announced today the successful completion of the Company's human clinical study testing the safety and efficacy of its patented drug, TK-90, to prevent the painful and dose-limiting mucositis caused by widely used cancer therapies.

TK-90 was [administered to 25 head and neck cancer patients receiving methotrexate](#) to determine the optimal dose of treatment as well as to confirm safety. [TK-90 proved effective in preventing virtually all of patients' mucositis](#) at the two higher doses tested. No TK-90 related side effects were observed in any patient group. A follow-up study is planned to confirm these results using the optimal dose and will be completed within the first half of 2019.

“Tosk’s mission is to improve the quality of life of cancer patients worldwide by providing them with highly effective, inexpensive drugs that eliminate toxic side effects and make certain drugs effective in patients that do not currently benefit from treatment,” Tosk’s CEO, Brian Frenzel, said. “Though side effect reduction is one of the 10 areas of emphasis in the U.S. government’s Cancer Moonshot initiative, it tends to be under appreciated. Side effects suffered by cancer patients not only reduce their quality of life but can force physicians to limit cancer treatment. Also, side effects are often expensive to treat, increasing the cost of care. Some cancer therapy side effects are permanent and reduce lifespan, even if the cancer is in remission. Our team at Tosk is dedicated to

“

Side effects suffered by cancer patients not only reduce their quality of life but can force physicians to limit cancer treatment. Also, side effects are often expensive to treat.”

*Brian Frenzel, CEO, Tosk, Inc.*

addressing these important, unmet medical needs.”

[Tosk has two other promising side-effect-reducing drugs in the pipeline.](#) TK-39 is a patented drug that blocks the cardiotoxicity caused by a class of widely-used cancer drugs known as the anthracyclines. These drugs are used to treat breast, bladder, and lung cancers, as well as lymphomas and leukemias. The damage to heart tissue from these drugs is permanent and limits the lifetime dosage of an otherwise effective cancer treatment. Tosk’s other side-effect-reducing drug, TK-88, is designed to block adverse effects caused by widely used platinum-based drugs, such as cisplatin and carboplatin. These side effects can include loss of kidney function, peripheral neuropathy, and hearing loss.

“The results of the TK-90 clinical study fully met our expectations,” said Frenzel. “The company has initiated a partner search to identify companies that would be a good fit for TK-90. We plan to grow and add other products to our pipeline using our proprietary discovery technologies, but we’ll let others take our drugs to market. These could include big pharma, specialty pharma, and supportive care oncology companies.”



Drug developer Tosk, Inc.,

## About Tosk, Inc.

Tosk's mission is to improve outcomes for cancer patients by discovering and developing new drugs that selectively block the adverse side effects of cancer therapies and make certain drugs effective in patients that currently do not benefit from treatment. Tosk uses proprietary drug screening methods using the common fruit fly to discover new drugs that might not be found using more conventional methods.

Brian Frenzel  
Tosk, Inc.  
408 245-6838  
[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.